Home / Companies / Zynerba Pharmaceuticals, Inc. / 25 Aug 2023
Zynerba Pharmaceuticals, Inc.: meeting of 25 Aug 2023
Votes reported on Form N-PX, item by item
51 Form N-PX filers reported votes at the Zynerba Pharmaceuticals, Inc. meeting of 25 Aug 2023. Their records fall into 6 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
7 nominees; 91.1% of reported votes for; 5 filers withheld from or voted against at least one nominee.
120 vote records from 12 filers. 0 of the 11 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
60 vote records from 50 filers. 1 of the 47 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.
One filer reported a share count too large to be the holding described. That figure is left out of the share split below; the count of filers includes it. How that is decided
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
17 vote records from 12 filers. 0 of the 11 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
34 vote records from 12 filers. 0 of the 11 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
18 vote records from 13 filers. 2 of the 12 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
17 vote records from 12 filers. 0 of the 11 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| State Street and SPDR | No report | For | No report |
| Equitable | For | For | For |
| Charles Schwab | For | For | For |
| Goldman Sachs | No report | For | No report |
| Northern Trust and FlexShares | For | For | For |
| Victory Capital | For | For | For |
| BNY Mellon | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Zynerba Pharmaceuticals, Inc. meeting?
51 Form N-PX filers reported votes at the meeting of 25 Aug 2023. On say-on-pay, 1 of 47 voted against management (2.1%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Zynerba Pharmaceuticals, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Zynerba Pharmaceuticals, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Zynerba Pharmaceuticals, Inc. with a meeting date within three days of 25 Aug 2023. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 30 Sep 2026.